CAI announced that Mike Martin, the firm’s current vice president of strategy and development, has been named to succeed Bob Chew as chief executive officer. Mr. Martin will assume the role of chief executive in January 2022, while Mr. Chew will continue to serve as chairman of the board. Mr. Martin will work with Mr. Chew and the board of directors to lead strategy and direction for CAI.
 
“We are pleased to announce that Mike Martin will become CAI president on November 1, 2020, pursuant to a transfer of CEO role in January 2022,” said Mr. Chew. “Mike completed a 30+ year career with Eli Lilly & Company, where he managed projects and led businesses in the U.S., Puerto Rico, China and Ireland. Since joining CAI in 2018, Mike has been the director of program and project management services, helping clients plan and execute complex projects. He is also head of CAI’s Strategic Development Council. Mike brings a wealth of experience in project delivery, operational readiness, regulated manufacturing, and business management.”
 
CAI is a full-service consulting firm that helps customers design, deliver, operate and maintain quality biopharma manufacturing or mission-critical facilities. CAI engineers, technical and consulting services encompass all aspects of operational excellence from equipment and automation to human performance.
 
Founded in 1996, CAI is a global, employee-owned company with offices in the U.S., Canada, Ireland, Italy, Netherlands, China, Singapore and Malaysia.